Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below 200 Day Moving Average of $5.16

Shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCELGet Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.16 and traded as low as $4.22. Cryo-Cell International shares last traded at $4.37, with a volume of 5,170 shares traded.

Cryo-Cell International Stock Performance

The stock has a market capitalization of $36.23 million, a P/E ratio of 14.57 and a beta of 0.35. The stock has a 50-day moving average price of $5.69 and a two-hundred day moving average price of $5.16.

Cryo-Cell International (NYSEAMERICAN:CCELGet Free Report) last released its quarterly earnings results on Thursday, October 12th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.13. Cryo-Cell International had a negative return on equity of 324.93% and a net margin of 8.03%. The company had revenue of $7.87 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cryo-Cell International stock. Cerity Partners LLC acquired a new stake in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCELFree Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 19,563 shares of the company’s stock, valued at approximately $83,000. Cerity Partners LLC owned about 0.23% of Cryo-Cell International at the end of the most recent quarter. 10.01% of the stock is owned by institutional investors.

Cryo-Cell International Company Profile

(Get Free Report)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

Featured Articles

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.